[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hôpital du Valais\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100633498","hismar-intraoperative-margin-assessment-using-the-histolog-scanner-to-reduce-reoperation-in-breast-conserving-surgery-100633498",false,"NCT07527468","HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery","HISMAR: A Prospective Post-Market Performance Follow-up Study of the Histolog Scanner for Intraoperative Margin Assessment in Breast-Conserving Surgery for High-Risk Histological Subtypes (ILC, DCIS, NST+DCIS)","HISMAR","1. Female patient, aged 18 years or older at time of surgery.\n2. Pre-operative core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) with histological diagnosis of one of the following:\n\n   1. invasive lobular carcinoma (ILC\u002FCLI),\n   2. pure ductal carcinoma in situ (DCIS), or\n   3. invasive carcinoma of non-special type (NST) with an associated DCIS component.\n3. Planned breast-conserving surgery (BCS \u002F lumpectomy) at CHVR.\n4. Signed electronic informed consent (eIC) obtained prior to any study procedure.\n\nExclusion Criteria:\n\n1. Pregnancy (confirmed or suspected) at time of surgery.\n2. Prior neo-adjuvant treatment (hormonal therapy or chemotherapy) for the current breast cancer diagnosis.\n3. Surgical indication for mastectomy rather than BCS.\n4. Known hypersensitivity or allergy to acriflavine (fluorescent staining agent used with the Histolog Scanner).\n5. Incapacity to provide informed consent.\n6. Previous enrolment in this study.","FEMALE","18 Years",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates whether systematic intraoperative margin assessment using the Histolog® Scanner - a confocal fluorescence microscopy device - reduces the need for reoperation after breast-conserving surgery (lumpectomy) in women with lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), or invasive carcinoma with a DCIS component (NST+DCIS).\n\nAfter lumpectomy, the fresh specimen is imaged in real time by the surgeon using the Histolog® Scanner, which produces histological-quality images of the specimen surface without any tissue processing. This allows immediate assessment of surgical margins in the operating room, enabling the surgeon to perform additional tissue removal if needed before closing.\n\nBased on institutional data from 266 cases at CHVR (2021-2024), the current reoperation rate in this population is 11.3%. The study tests whether systematic use of the Histolog® Scanner in addition to standard care reduces this rate by 50% or more (to ≤5.6%). A total of 228 patients will be enrolled prospectively at the Centre Hospitalier du Valais Romand (CHVR), Sion, Switzerland. The reoperation decision is made by the multidisciplinary tumour board based on final histopathology results, independently of the intraoperative findings.",[27,28,29,30],"Breast Cancer","Ductal Carcinoma In Situ","Invasive Lobular Carcinoma","Breast Neoplasm Female",[32,33,34,35,36,37,38,39,40,41,42,43],"breast-conserving surgery","lumpectomy","surgical margins","intraoperative imaging","confocal microscopy","reoperation","re-excision","histological scanning","DCIS","ILC","post-market performance follow-up","PMPF","NOT_YET_RECRUITING","2026-04-07",{"date":47,"type":48},"2026-04-14","ACTUAL",{"date":50,"type":21},"2026-09-01",{"date":52,"type":21},"2030-06-01",{"name":54,"class":55},"Hôpital du Valais","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100629802","effect-of-pre-operative-exercise-training-on-cardiorespiratory-fitness-in-patients-with-locally-advanced-non-small-cell-lung-cancer-undergoing-induction-chemo-immunotherapy-followed-by-surgery---a-randomized-controlled-study-100629802","NCT07479407","Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study","PREHAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Confirmed diagnosis of stage IIB, IIIA, IIIB or oligo-metastatic stage IV NSCLC.\n* Planned induction therapy with either chemotherapy, immunotherapy or a combination of immuno-chemotherapy followed by an anatomical pulmonary resection.\n* Absence of musculoskeletal conditions preventing safe physical exercise.\n* Absence of any history of uncontrolled or unstable cardiac disease.\n* Agreement to participate in the study by signing the study specific informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy (confirmed by a test if applicable).\n* Induction therapy already initiated.\n* Inability to walk independently.\n* Lack of decision-making capacity.\n* Oxygen-dependency before the initiation of the induction protocol.\n* No capacity for discernment.\n* Does not speak French.","ALL",{"count":66,"type":21},74,[24],"The PREHAB study focuses on patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemotherapy and\u002For immunotherapy prior to surgical resection. These systemic treatments frequently impair patients' physiological reserve, reduce physical fitness, and may occasionally lead to cancellation of surgery. Surgery itself carries a substantial risk of cardiorespiratory complications and long-term functional decline.\n\nThe primary objective of this study is to determine whether a supervised exercise program, initiated concomitantly with systemic therapy and continued until surgery, can improve cardiorespiratory fitness, surgical tolerance, and postoperative outcomes.\n\nA total of 74 patients will be randomly assigned to one of two groups: an \"intervention\" group participating in three weekly sessions of supervised endurance and resistance training for 12 to 16 weeks under the guidance of a physiotherapist, and a \"control\" group receiving usual care without a structured exercise program.\n\nThe primary endpoint will be peak oxygen uptake (VO₂peak). Secondary outcomes will include postoperative complication rates, length of hospital stay, pulmonary function, skeletal muscle mass, and quality of life.\n\nIntervention-related risks, primarily falls or overexertion, will be mitigated through professional supervision. This multicenter study, with recruitment scheduled to begin in 2026, is expected to provide robust evidence regarding the effectiveness of targeted exercise training in improving preoperative fitness and postoperative recovery in patients with locally advanced NSCLC.",[70],"Locally Advanced Non-small Cell Lung Cancer (NSCLC)",[72,73,74,75,76,77,78,79,80,81],"Non-small cell lung cancer","Locally advanced NSCLC","Neoadjuvant therapy","Immunotherapy","Prehabilitation","Exercise training","VO2peak","Cardiopulmonary exercise testing","Thoracic surgery","Postoperative complications","2026-03-16",{"date":84,"type":48},"2026-03-18",{"date":86,"type":21},"2026-04",{"date":88,"type":21},"2029-04",{"name":54,"class":55},3,""]